Second French Trial Tragedy Verdict: No Danger Signs In Lower Dose Triallists
A second committee has given its opinion on the Phase I trial tragedy in France earlier this year in which one volunteer died and four others were hospitalized after suffering neurological damage. The panel found that while some neurological signals were seen in about half of the other 80-odd volunteers, these were in line with what would be expected in a first-in-human clinical trial and differed from the lesions seen in the volunteers who were hospitalized.
You may also be interested in...
The French health minister, Marisol Touraine, says that she intends to send the dossiers on the 90 volunteers who took part in the disastrous Phase I FAAH inhibitor study in Rennes to the working groups that have been set up at EU level to look into possible changes to the EU guidelines on first-in-man studies1,2.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation.